ACC/AHA/NHLBI clinical advisory on the use and safety of statins

Circulation

Volumn 106, Issue 8, 2002, Pages 1024-1028

  Pasternak, Richard C ^a   Smith Jr , Sidney C ^a   Bairey Merz, C Noel ^a   Grundy, Scott M ^a   Cleeman, James I ^a   Lenfant, Claude ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CHOLESTEROL BLOOD LEVEL; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFECT; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DYSPEPSIA; FOOD AND DRUG ADMINISTRATION; HEADACHE AND FACIAL PAIN; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; MYOPATHY; MYOSITIS; OUTCOMES RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT; RISK FACTOR; TREATMENT INDICATION;

AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; CORONARY DISEASE; CREATINE KINASE; DRUG INTERACTIONS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; MUSCULAR DISEASES; PYRIDINES; RISK FACTORS;

EID: 0037143688     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000032466.44170.44     Document Type: Review

References (36)

1. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
2. Results of the Heart Protection Study
3. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study
4. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
5. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
6. Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials
7. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
8. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
9. Lipid-lowering drugs and risk of myopathy: A population-based follow-up study
10. Cerivastatin and reports of fatal rhabdomyolysis
11. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia
12. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia
13. Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: A reappraisal
14. HMG-CoA reductase inhibitors. A new approach to the management of hypercholesterolemia
15. Drug treatment of dyslipoproteinemia
16. Nonalcoholic fatty liver disease
17. Statins and risk of polyneuropathy: A case-control study
18. Learning from the cerivastatin experience
19. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy
20. The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis
21. Use of HMG-CoA reductase inhibitors after kidney and heart transplantation: Lipid-lowering and immunosuppressive effects
22. Drug interactions with HMG CoA reductase inhibitors
23. Does differing metabolism by cytochrome p450 have clinical importance?
24. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin
25. Fibrates and statins in the treatment of hyperlipidaemia: An appraisal of their efficacy and safety
26. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia
27. Safety of combined pravastatin-gemfibrozil therapy
28. Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders
29. Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia
30. Randomized crossover study of gemfibrozil versus lovastatin in familial combined hyperlipidemia: Additive effects of combination treatment on lipid regulation
31. Long-term treatment with pravastatin alone and in combination with gemfibrozil in familial type IIB hyperlipoproteinemia or combined hyperlipidemia
32. Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia
33. HMG CoA reductase inhibitor-induced myotoxicity: Pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture
34. Differential sensitivity of C2-C12 striated muscle cells to lovastatin and pravastatin
35. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle
36. Lovastatin increases exercise-induced skeletal muscle injury